ENTEROPATHY-ASSOCIATED T-CELL LYMPHOMA
Clinical trials for ENTEROPATHY-ASSOCIATED T-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new ENTEROPATHY-ASSOCIATED T-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for ENTEROPATHY-ASSOCIATED T-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take aim at Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-phase trial tests whether a patient's own immune cells, modified in a lab to recognize and attack a protein called CCR4 on cancer cells, can safely treat certain T-cell lymphomas that have not responded to standard therapy. About 60 adults with relapsed or refractory p…
Matched conditions: ENTEROPATHY-ASSOCIATED T-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New drug trial targets rare and aggressive blood cancers
Disease control Recruiting nowThis is the first study in humans to test a new drug called DR-01 for adults with rare and aggressive blood cancers, including large granular lymphocytic leukemia and several types of cytotoxic lymphomas. The main goals are to find a safe dose and see if the drug can shrink tumor…
Matched conditions: ENTEROPATHY-ASSOCIATED T-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Dren Bio • Aim: Disease control
Last updated Apr 06, 2026 14:05 UTC